Skip to main content
. Author manuscript; available in PMC: 2020 Sep 11.
Published in final edited form as: Leukemia. 2020 Feb 24;34(9):2342–2353. doi: 10.1038/s41375-020-0764-6

Figure 2. Ibrutinib + Venetoclax combination is potent and synergistic in AML cells.

Figure 2.

A. Evaluation of IBR and VEN alone and in combination on two healthy donor bone marrow samples. B. Evaluation of IBR and VEN alone and in combination on MOLM14 AML cells. C. Surface plot of IBR+VEN synergy (ZIP score) generated from a 7×7 dose matrix on MOLM14 AML cells. Synergy was calculated with R_SynergyFinder. D. Schematic of in vivo xenograft study. E. Levels of human CD45-positive cells in peripheral blood of NSG mice injected with MOLM13 cells and treated with vehicle, venetoclax (25 mk/kg), ibrutinib (25 mg/kg) or the combination IBR+VEN (25 mg/kg each). FDR-adjusted p-values are indicated for comparisons with the combination.